Literature DB >> 21237716

Immunological correlates of protection for the RTS,S candidate malaria vaccine.

Brian Greenwood1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21237716     DOI： 10.1016/S1473-3099(11)70001-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  6 in total

1.  Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites.

Authors:  Noah S Butler; Nathan W Schmidt; Ashley M Vaughan; Ahmed S Aly; Stefan H I Kappe; John T Harty
Journal:  Cell Host Microbe       Date:  2011-06-16       Impact factor: 21.023

2.  Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.

Authors:  Patrick Georges Cech; Thomas Aebi; Mwanajaa Shomari Abdallah; Maxmillian Mpina; Ester Barnabas Machunda; Nicole Westerfeld; Sabine Alexandra Stoffel; Rinaldo Zurbriggen; Gerd Pluschke; Marcel Tanner; Claudia Daubenberger; Blaise Genton; Salim Abdulla
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

Review 3.  Immunization in travel medicine.

Authors:  Suzanne Moore Shepherd; William Hudson Shoff
Journal:  Prim Care       Date:  2011-12       Impact factor: 2.907

4.  Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Authors:  Caroline Ogwang; Muhammed Afolabi; Domtila Kimani; Ya Jankey Jagne; Susanne H Sheehy; Carly M Bliss; Christopher J A Duncan; Katharine A Collins; Miguel A Garcia Knight; Eva Kimani; Nicholas A Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C Gilbert; Alexandra J Spencer; Peninah Soipei; Jenny Mueller; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K Viebig; Rachel Roberts; Katherine Gantlett; Alison M Lawrie; Alfredo Nicosia; Egeruan B Imoukhuede; Philip Bejon; Britta C Urban; Katie L Flanagan; Katie J Ewer; Roma Chilengi; Adrian V S Hill; Kalifa Bojang
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

5.  Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines.

Authors:  Freya J I Fowkes; Julie A Simpson; James G Beeson
Journal:  BMC Med       Date:  2013-10-30       Impact factor: 8.775

6.  Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.

Authors:  Hayley A Thompson; Alexandra B Hogan; Patrick G T Walker; Michael T White; Aubrey J Cunnington; Christian F Ockenhouse; Azra C Ghani
Journal:  Vaccine       Date:  2020-10-09       Impact factor: 3.641
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.